Hong Kong Local Responsible Person

Companies seeking to sell their medical devices in Hong Kong or IVD products to Hong Kong public hospitals must be listed in the MDACS (Medical Device Administrative Control System) database to meet procurement preference criteria.

Only a Local Responsible Person (LRP), which must be a registered Hong Kong entity, can handle the Listing application and perform various responsibilities such as managing regulatory obligations.

In addition, the Local Responsible Person has responsibility for post-market surveillance (PMS) such as adverse event reporting and ensures labeling compliance. Having an independent third party as an LRP can provide more control over the registration process and greater flexibility in managing distributors. Local Responsible Persons can also facilitate procurement processes for public hospitals, as MDACS-listed products receive preference.

Companies must apply for various classifications and registrations to ensure compliance with local health authorities and market readiness.

Conformity assessment body
Public health

Can I Change My Hong Kong Local Responsible Person?

Yes, appointing a new Hong Kong Local Responsible Person is possible. Manufacturers often consider this when dissatisfied with their current agent, especially if the agent is also their distributor. In such cases, appointing an independent LRP like Cisema can provide greater transparency and control. Additionally, the benefits of appointing an independent Local Responsible Person include enhanced flexibility in distribution strategies and improved compliance with regulatory requirements.

Can I Become My Own Local Responsible Person in the Future?

Yes, this is quite common for manufacturers who grow and wish to establish their own operations in Hong Kong. This local company must satisfy the Hong Kong MDD’s regulatory requirements and is legally responsible for compliance during the entire product life cycle - which includes product registration, post market surveillance, and communication with authorities.

Cisema can remain contracted to help with communications and post market surveillance. Some manufacturers may take on this responsibility themselves once their local operations are ready. Handling these tasks in-house allows for better oversight. However, it requires hiring people who understand the regulatory rules in Hong Kong and any changes to them. Having a Local Responsible Person (LRP) to manage these regulatory obligations is crucial for IVD and medical device companies to ensure compliance and smooth operations.

Clinical Development Services 

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Only a Local Responsible Person (LRP), which must be a registered Hong Kong entity, can handle the Listing application and perform various responsibilities such as managing regulatory obligations.

In addition, the Local Responsible Person has responsibility for post-market surveillance (PMS) such as adverse event reporting and ensures labeling compliance. Having an independent third party as an LRP can provide more control over the registration process and greater flexibility in managing distributors. Local Responsible Persons can also facilitate procurement processes for public hospitals, as MDACS-listed products receive preference.

Companies must apply for various classifications and registrations to ensure compliance with local health authorities and market readiness.

Request a Proposal from our Life Sciences Team about Appointing Us as Your Local Responsible Person LRP in Hong Kong

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

Cisema Launches a Redesigned Website

Learn about Cisema’s redesigned website with faster performance, clearer navigation and expanded Asia Pacific coverage.

May 6, 2026
Cisema Launches a Redesigned Website
Cisema Logo: Navigating Regulation, Empowering Innovation

GBA Connect Scheme: Using Real World Data to Support China NMPA Approval

Discover how leveraging Real World Data generated in the Greater Bay Area can accelerate market entry for medical products in China.

April 23, 2026
GBA Connect Scheme: Using Real World Data to Support China NMPA Approval
GBA Connect Scheme: Using Real World Data to Support China NMPA Approval
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Hong Kong Medical Device Registration

We assist you through every step of the Hong Kong Medical Device Listing process, ensuring compliance with Medical Device Division requirements. Expedited pathways are available, and we will determine if those are feasible.

Learn more

Hong Kong IVD Registration

We support you through every stage of the Hong Kong IVD Listing process. From classification to handling regulatory requirements, we make the process as smooth as possible.

Learn more

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-market sampling inspections and regular standard changes. Our specialist PMS team means you stay up to date with the many aspects of compliance.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Latest Insights

View More

Hong Kong Launches Primary Evaluation Phase 1 for NDAs

Hong Kong introduces Primary Evaluation Phase 1 for NDAs, requiring pathway selection across 3 routes and reshaping drug registration strategy.

May 6, 2026
Hong Kong Launches Primary Evaluation Phase 1 for NDAs
A single Asian scientist in their 30s wearing a lab coat, safety glasses, and nitrile gloves seated at a tidy bench in a modern pharmaceutical laboratory in Hong Kong, calmly reviewing a few printed documents while referencing a simple laptop screen

Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138

Hong Kong confirms injectable products are generally classified as pharmaceutical products under Cap. 138, impacting medical aesthetics and borderline products

May 8, 2026
Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138
Minimalist, well-lit medical aesthetics clinic in Hong Kong. An Asian female doctor in a simple white coat and disposable gloves sits beside a female patient, holding a single unbranded prefilled syringe at chest level.

Hong Kong to Regulate Medical Gases as Pharmaceutical Products from June 2026

Learn the registration requirements, scope, and compliance steps as Hong Kong regulates medical gases as pharmaceutical products.

April 23, 2026
Hong Kong to Regulate Medical Gases as Pharmaceutical Products from June 2026

Guangdong MPA Publishes 2025 GBA Connect Scheme Medical Products Catalogue

Guangdong’s MPA and Health Commission issued the 2025 GBA Connect “urgently needed” catalogue covering 115 Hong Kong–Macao drugs and devices.

March 31, 2026
Guangdong MPA Publishes 2025 GBA Connect Scheme Medical Products Catalogue
Previous
Previous

Contact Our Life Sciences Team

And discover how we can support you as your Local Responsible Person in applying for regulatory approval in Hong Kong.

Request Proposal